San Francisco: The COVID-19 pandemic could extend till 2024 as the lower-dose version of its vaccine for 2-4 years olds generated a weaker immune response than expected, Pfizer Inc said on Friday.
Pfizer has developed the vaccine with Germany’s BioNTech SE. While a 3-microgram dose of its vaccine was tested on 2-5 year-olds, a 10-microgram dose was used in 5-11 year-olds and 30-microgram doses in everyone over 12. In children aged 6 to 24 months, the low-dose version of the vaccine generated an immune response consistent with that of older vaccine recipients, Reuters reported.
The company said it had expected data of its testing of three-dose course of the vaccine in all age groups under 16, including 2-4-year-olds, this year. Despite the delay, it would go ahead and file for emergency use authorization in the second quarter of 2022.
“The data are illustrating the impact of a booster and that our vaccine works best as a primary regimen of three doses,” Pfizer chief scientific officer Mikael Dolsten said on a conference call.
Mumbai: After beau Arjun Kapoor declared publicly that he is not dating anyone right now,…
Mumbai: Even though Aishwarya Rai and Abhishek Bachchan have maintained a dignified silence over their…
Bhubaneswar: Siddhant Das has sought to step down as Chairman of Odisha Real Estate Regulatory…
Hyderabad: Odisha FC went on a scoring spree at the Gachibowli Stadium as they humbled hosts…
Mumbai: Filmmaker Anurag Kashyap’s directorial debut ‘Paanch’ is finally going to see the light of…
Mumbai: Actress Taapsee Pannu, who has shared screen space with very few A-listers, has now…
Bhubaneswar: Vigilance has arrested a Forester and a Gaon Sathi (village mate) for alleged misappropriation…
Mumbai: Ten days ago, Vaibhav Suryavanshi made headlines after becoming the youngest cricketer to make…